Zydus receives USFDA tentative approval for Febuxostat Tablets
Capital MarketZydus Cadila has received a tentative approval for Febuxostat Tablets (US RLD Uloric), 40 mg and 80 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. It is used to treat hyperuricemia (constantly high levels of uric acid) in adults who have gout. It helps in decreasing symptoms of gout which include pain, swelling, redness, heat, soreness, and stiffness in certain joints.
Powered by Capital Market - Live News